GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzamend Neuro ALZN · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.42

+0.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Net income

−$8.8m

FY2017FY2026

Free cash flow

−$8.1m

FY2017FY2026

Shareholders' equity

$733,211

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross profit—−$50,740−$50,740−$23,066——————
Research and development$3.6m$1.4m$6.5m$7.4m$5.2m$1.3m$1.1m$3.7m$323,403$275,047
Operating income−$8.8m−$4.5m−$9.9m−$14.9m−$12.3m−$5.0m−$4.4m−$5.0m−$898,000−$1.5m
Net income−$8.8m−$4.5m−$9.9m−$14.9m−$12.4m−$5.0m−$4.4m−$4.9m−$932,000−$1.6m
Diluted earnings per share-1.96-1.34-25.35-204.09-171.22-72.93-82.17-92.62-24.72-64.34

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$2.1m$4.6m$631,588$5.9m$14.5m$2.9m$1.8m$1.5m$2.4m$132,293
Cash and short-term investments$710,689$3.9m$376,048$5.1m$14.1m$1.9m$90,285$42,606$545,000$4,976
Total liabilities$1.3m$634,761$3.2m$2.9m$1.2m$899,643$992,306$1.2m$96,724$717,223
Debt——$300,714——$335,303$63$79—$591,258
Shareholders' equity$733,211$4.0m−$2.6m$3.0m$13.4m$2.0m$821,709$316,915$2.3m−$584,930
Shares outstanding4m3m0m0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$8.1m−$6.6m−$8.3m−$8.9m−$6.6m−$2.7m−$2.3m−$1.0m−$2.1m−$1.4m
Capital spending—−$300,000−$147,243—−$106,458−$106,458−$106,458−$106,458——
Free cash flow−$8.1m−$6.9m−$8.4m−$8.9m−$6.7m−$2.8m−$2.5m−$1.2m−$2.1m−$1.4m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Gross profit−$27,685−$27,685−$27,685−$27,685−$27,685−$12,685−$12,685−$12,685
Operating income−$3.0m−$2.9m−$2.2m−$998,109−$2.7m−$1.1m−$1.0m−$1.4m
Net income−$3.0m−$2.9m−$2.2m−$1.0m−$2.7m−$1.1m−$1.0m−$1.4m
Diluted earnings per share-0.68-0.64-0.49-0.30-0.80-0.34-0.31-3.47
Cash from operations−$1.0m−$2.0m−$1.0m−$1.0m−$2.0m—−$1.0m−$3.0m
Total assets$8.5m$2.1m$4.0m$5.1m$6.3m$4.6m$4.2m$5.0m
Cash and short-term investments$7.6m$710,689$2.7m$4.4m$5.6m$3.9m$3.4m$4.1m
Shareholders' equity$5.8m$733,211$2.2m$4.4m$5.3m$4.0m$3.4m$3.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-16.1%12.1%62.2%
Net income-16.1%11.7%62.2%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.8-1.4-0.4-0.4-4.5-35.2

Share price return

Finished calendar years

20252024202320222021
Return-80%-87%-92%-60%-84%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 9-to-1 reverse split · 12 May 2025
  • 10-to-1 reverse split · 16 Jul 2024
  • 15-to-1 reverse split · 31 Oct 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.